Top 10 most anticipated drug launches of 2024 | Fierce Pharma
Every year, we tap Evaluate's annual preview report to assess the biggest potential new drugs of the year ahead. Typically, major pharmaceutical and biotechnology companies are featured, each ...
Top 20 pharma companies by 2023 revenue - Fierce Pharma
There were changes at the top and the bottom of last year’s top 20 pharma rankings by revenue. And, in between, Novo Nordisk made a significant leap, jumping five spots propelled by skyrocketing ...
Gilead’s Kite shortens Yescarta manufacturing time with FDA nod
Jan 30, 2024 · The manufacturing upgrade comes as Kite works through an important launch for Yescarta as a second-line therapy for large B-cell lymphoma. Last month, the FDA allowed additional patient survival ...
Appeals court again strikes down J&J's Texas two-step ploy
Jul 26, 2024 · Johnson & Johnson’s latest attempt to get a handle on its talc litigation using the controversial Texas two-step bankruptcy strategy has once again fallen flat after a federal appeals court ...
Lilly's Mounjaro will be in short supply through April, FDA says
Apr 2, 2024 · The company acknowledged that some patients may struggle to fill their prescriptions due to “the unprecedented demand for these medicines,” a Lilly spokesperson recently told Fierce Pharma ...
UPDATED: FDA lists all doses of Novo's Wegovy as available, …
Oct 31, 2024 · Elsewhere, Novo Holdings, which acts as a holding company for the drugmaker, revealed plans to purchase contract manufacturing giant Catalent for $16.5 billion in early February. As part of the ...
In long-awaited deal, Sun finally buys out Taro for $348M - Fierce …
Jan 18, 2024 · In May of last year, Sun revealed that it had offered to buy outstanding shares of the company for $38 each, with that proposal coming to $307 million.. Last month, Sun said that it had upped its ...
The top 20 drugs by worldwide sales in 2023 | Fierce Pharma
It's been several years since COVID-19 vaccines from Pfizer and Moderna jumped to the top of the pharma industry's sales charts, displacing longtime stalwarts with unprecedented sales. But, as ...
Iterum nabs FDA approval for oral UTI drug after prior rejection
Oct 25, 2024 · Despite recent concerns from the FDA about potential off-label use and antimicrobial resistance, Dublin-based Iterum Therapeutics has scored a green light for its oral antibiotic sulopenem.
FDA removes Lilly's Mounjaro and Zepbound from its shortage list
Oct 3, 2024 · Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, freeing the company from competing with compounding pharmacies that have ...